AlexVladimir(Mejia)Mejia GarciaMD

PubMed

• 1 citations
  A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, I Brian Greenwell, Brian T Hess, Krista M Isaac, Craig A Portell, Alex Mejia Garcia...> ;Blood Advances. 2023 Jul 11
• 7 citations
  Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
  Brian T Hess, Anshu Giri, Yeonhee Park, Krina K Patel, Brian K Link, Grzegorz S Nowakowski, Seth M Maliske, Sonia Fortin, Julio C Chavez, Hayder Saeed, Brian T Hill, A...> ;American Journal of Hematology. 2023 Feb 1
• Unusual case of blastoid cells with bilobed nuclei: Cottage loaves, sliding plates, and butterflies.
  Emad Ababneh, Alex V Mejia Garcia, Megan O Nakashima> ;Ejhaem. 2021 Nov 1
• 7 citations
  Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy.
  Rajshekhar Chakraborty, Lisa Rybicki, Jason Valent, Alex V. Mejia Garcia, Beth Faiman, Jack Khouri, Christy J. Samaras, Faiz Anwer, Alok A. Khorana> ;Blood Cancer Journal. 2021 Jun 25
• 17 citations
  Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
  Fahrettin Covut, Ramsha Ahmed, Sanchit Chawla, Frank Ricaurte, Christy J. Samaras, Faiz Anwer, Alex V. Mejia Garcia, Dana E. Angelini, Sandra Mazzoni, Beth Faiman, Jas...> ;British Journal of Haematology. 2021 May 17
• 25 citations
  Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
  Kevin R. Kelly, Alex Mejia, Avvaru N. Suhasini, An Ping Lin, John G. Kuhn, Anand B. Karnad, Steven D. Weitman, Ricardo C.T. Aguiar> ;Clinical Cancer Research. 2017 Mar 1
• 5 citations
  Eligibility of patients with renal impairment for Phase I trials: Time for a rethink?
  Laeeq Malik, Alex Mejia, Steven D. Weitman> ;European Journal of Cancer. 2014 Nov 1
• Advanced Thyroid Cancer Patients in Phase I Clinical Trials: Outcome Assessment and Literature Review
  Laeeq Malik, Alex Mejia> ;World Journal of Oncology. 2014 Nov 21
• 6 citations
  Predicting success in regulatory approval from Phase I results
  Laeeq Malik, Alex Mejia, Helen Parsons, Benjamin Ehler, Devalingam Mahalingam, Andrew Brenner, John Sarantopoulos, Steven D. Weitman> ;Cancer Chemotherapy and Pharmacology. 2014 Sep 23
• 3 citations
  Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials
  Laeeq Malik, Helen Parsons, Devalingam Mahalingam, Benjamin Ehler, Martin Goros, Alex Mejia, Andrew Brenner, John Sarantopoulos> ;Clinical Genitourinary Cancer. 2014 Oct 1
• 9 citations
  How well informed is the informed consent for cancer clinical trials
  Laeeq Malik, James C Kuo, Desmond Yip, Alex Mejia> ;Clinical Trials. 2014 Aug 18
• 7 citations
  Informed consent for phase I oncology trials: form, substance and signature.
  Laeeq Malik, Alex Mejia> ;Journal of Clinical Medicine Research. 2014 Mar 31
• Molecular staging individualizing cancer management.
  Mejia, A., Schulz, S., Hyslop, T., Weinberg, D. S., Waldman, S. A.> ;J Surg Oncol. 2012 Apr 1
• Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Patients.
  Reitman, M., Dishy, V., Moreau, A., Denney, W.S., Liu, C., Kraft, W.K., Mejia, A.V., Matson, M.A., Stoch, S.A., Wagner, J.A., Lai, E.> ;J Clin Pharmacol. 2012 Sep
• Join now to see all